drugset / Trial / NCT03596970

Study of the Effect of Everolimus Immunosuppressive Combination Therapies on Renal Function When Used as a Maintenance Treatment for Liver Transplant Patients.

NCT03596970

Phase 3 Withdrawn Novartis Pharmaceuticals
RandomizedParallel-groupOpen-labelTreatment

Summary

A 24-month multi-center, open-label, randomized, controlled study to evaluate the evolution of renal function in maintenance liver transplant recipients receiving everolimus plus reduced TAC or everolimus plus mycophenolate mofetil (MMF)

Timeline

Start
2015-09
Primary completion
2020-12
Completion
2020-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Everolimus Small molecule
Comparator Everolimus with reduced TAC Unknown
Subject Mycophenolate Mofetil Small molecule

Indications

No indication recorded.